ClinicalTrials.gg
RecruitingNCT05197270Updated Aug 21, 2026

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

A Phase 1/2 interventional study of 4D-150 IVT and Aflibercept IVT in Neovascular (Wet) Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics. Recruiting at 26 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by 4D Molecular Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Planned enrollment
109th of 491
215 · median 55
Started
2021
with 27 others
Phase 1/2
61 of 645
7 open now
Primary completion
2027-03
later than 45 of 124 live
Registered
499th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 109th largest by planned enrollment of the 491 interventional ones that give a count, is one of 28 that started in 2021, is one of 61 in phase 1/2, reaches primary completion later than 45 of the 124 other live ones, and was the 499th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.

Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.

Read the detailed description

This Phase 1/2 trial is a prospective, multicenter, Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment who have demonstrated a clinical response consistent with anti-VEGF activity. The trial consists of Dose Escalation, Dose Expansion, Steroid Optimization, and Population Extension Cohorts.

After receiving one time administration of 4D-150 by intravitreal injection (IVT), subjects will undergo assessments at monthly intervals for 24 months to assess safety and efficacy outcomes. Only subjects that received 4D-150 will then enter a long-term follow-up (LTFU) period to assess long-term safety of 4D-150 gene therapy and duration of clinical activity through year 5 (60 months).

Eligible subjects who received 4D-150 in the study eye may participate in a sub-study to evaluate one-time IVT administration of 4D-150 to the contralateral ("fellow") eye.

Additional subjects will be enrolled in a separate sub-study to characterize the vector shedding profile of one-time administration of IVT 4D-150.

In both sub-studies, subjects will undergo regular assessments to assess safety and tolerability through Week 52 and then will enter long-term follow-up for safety evaluation through year 5 (60 months).

03

Conditions studied

  • Neovascular (Wet) Age-Related Macular Degeneration

Keywords

  • Age-related macular degeneration
  • AMD
  • Exudative AMD
  • Exudative age-related macular degeneration
  • Neovascular AMD
  • Neovascular age-related macular degeneration
  • Wet age-related macular degeneration
  • Wet macular degeneration
  • Wet AMD
  • wAMD
  • Retinal gene therapy
  • Intravitreal gene therapy
  • Genetic Medicine
  • Ocular Gene Therapy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • 50 years of age

Individuals eligible to participate in the trial must meet the following inclusion criteria:

  1. ≥50 years of age
  2. Diagnosed with CNV secondary to AMD (confirmed by reading center)
  3. BCVA ≥34 ETDRS letters (\~20/200) in the contralateral eye, and BCVA in the study eye:
  4. Central subfield thickness (CST) and/or presence of subretinal or intraretinal fluid requiring continued anti-VEGF therapy in the study eye, as assessed by SD-OCT; and confirmed by a reading center):
  5. Study eye amenable to IVT injection
  6. Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures
  7. Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye AND has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening:

    Note: Day -7 aflibercept will be administered ≥ 4 weeks from last IVT anti-VEGF

  8. Subjects receiving 4D-150 agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period
  9. Medical records available to document history of anti-VEGF therapy (dates, drugs, and dosage) for a minimum of 12 months prior to Screening
  10. Provide written .

Contralateral Eye Sub-study-Specific Criteria:

  1. Received 4D-150 in study eye-1 at least 6 months prior to Contralateral Substudy Screening Visit NOTE: Subjects who received 4D-150 in study eye-1 as part of the Shedding Substudy are also eligible to participate in the Contralateral Eye Substudy only after biological samples from all matrices were at or below the limit of quantitation for vector genomes in at least 3 consecutive measurements AND at least 6 months has passed since 4D-150 administration to study eye-1.
  2. Macular neovascularization (MNV) secondary to AMD in study eye-2 as assessed on historical images at any time by SD-OCT (required) and FA when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by the reading center)
  3. History of at least 1 anti-VEGF injection in study eye-2 within 6 months prior to Screening (last anti-VEGF injection must be at least 28 days prior to Day 7) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time point prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)
  4. BCVA between 25 and 83 ETDRS letters, inclusive (20/320 20/25 Snellen) in study eye-2
  5. Study eye-2 amenable to IVT injection
  6. BCVA ≥34 ETDRS letters (\~20/200) in the previously treated study eye-1
  7. Ability to comply with protocol-specified procedures and visits, in the Investigator's judgment
  8. Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to study eye-2 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period
  9. Provide written informed consent.

Shedding Substudy-specific Inclusion Criteria:

  1. ≥50 years of age
  2. Diagnosed with MNV secondary to AMD as assessed on historical images at any time by spectral domain optical coherence tomography (SD-OCT) (required) and fluorescein angiography when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by Reading Center)
  3. Best corrected visual acuity (BCVA) between 10 and 83 ETDRS letters, inclusive (\~20/640 and 20/25, respectively) in the study eye at Screening
  4. BCVA ≥34 ETDRS letters (\~20/200) in the contralateral eye
  5. Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye; minimum of 1 injection within the last 6 months (last anti-VEGF injection must be at least 28 days prior to Day 7) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)
  6. Study eye amenable to IVT injection
  7. Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures, in the Investigator's judgment
  8. Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period
  9. Provide written informed consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
215 participants (estimated)

Study arms

  • Experimental
    4D-150 Dose Escalation up to 4 dose levels

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Dose Expansion Dose 1

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Dose Expansion Dose 2

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Active comparator
    4D-150 Dose Expansion Control

    Aflibercept at a fixed regimen will be administered.

    Biological: Aflibercept IVT

  • Experimental
    4D-150 Steroid Optimization

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Population Extension Dose 1

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Population Extension Dose 2

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Population Extension Dose 3

    4D-150 will be administered at the assigned dose

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Contralateral Eye Dose

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Vector Shedding Dose

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

Interventions

  • Biological4D-150 IVT

    4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept

  • BiologicalAflibercept IVT

    Commercially available Active Comparator Other Name: Eylea

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters

    Time frame: 52 weeks

Secondary outcomes

  1. Time to receiving the first supplemental aflibercept injection

    Time frame: 52 weeks

  2. Percentage of subjects requiring supplemental aflibercept injections over 52 weeks

    Time frame: 52 weeks

  3. Number of supplemental aflibercept injections over 52 weeks

    Time frame: 52 weeks

  4. Change from baseline in BCVA over time (up to 52 weeks) as assessed using the ETDRS Visual Acuity Chart

    Time frame: 52 weeks

  5. Change from baseline in central subfield thickness (CST) over time (up to 52 weeks) measured by spectral domain optical coherence tomography (SD-OCT)

    Time frame: 52 weeks

  6. Percent Change in Annualized Mean Number of anti-VEGF IVT injections before and after the 4D-150 injection

    Percent change in annualized mean number of anti-VEGF IVT injections before and after the 4D-150 injection (or Day 1 for the aflibercept only arm)

    Time frame: Before and after the 4D-150 injection (or Day 1 for the aflibercept only arm)

07

Study locations

21 of 26 sites recruiting
08

References and documents

Publications

  • Calton MA, Croze RH, Burns C, Beliakoff G, Vazin T, Szymanski P, Schmitt C, Klein A, Leong M, Quezada M, Holt J, Bolender G, Barglow K, Khoday D, Mason T, Delaria K, Hassanipour M, Kotterman M, Khanani AM, Schaffer D, Francis P, Kirn D. Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies. Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):1. doi: 10.1167/iovs.65.14.1. PubMed 39620832 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2027, 63 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 19, 2022
StartActual
Dec 9, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Jan 2031
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05197270
Lead sponsor
4D Molecular Therapeutics
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Dec 9, 2021
Primary completion
Mar 2027 (estimated)
Completion
Jan 2031 (estimated)
Last update
Aug 21, 2026

Study contacts

4DMT Patient Advocacy
Contact
clinicaltrials@4DMT.com
(888) 748-8881
Demi Dang, MD
study director · 4D Molecular Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion